US · XRTX
XORTX Therapeutics Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Vancouver, BC T2P 4K9
- Website
- xortx.com
Price · as of 2025-12-31
$2.78
Market cap 1.55M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $110.97 | ||||
| 2022 | $43.25 | ||||
| 2023 | $4.77 | ||||
| 2024 | $0.97 | ||||
| 2025 | $0.42 |
AI valuation
Our deep-learning model estimates XORTX Therapeutics Inc.'s (XRTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.78
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| XRTX | XORTX Therapeutics Inc. | $2.78 | 1.55M | — | — | — | — | -0.75 | 0.97 | — | -0.37 | — | 1.07 | 0.00% | — | — | -119.80% | -346.54% | -95.46% | 0.02 | — | 1.61 | 1.58 | 0.26 | -5273.00% | — | 398.00% | -139.13% | -4.71 | -294.67% | 0.00% | 0.00% | 0.00% | -0.36 | -0.43 | — | -14.31 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| GTBP | GT Biopharma, Inc. | $0.48 | 5.08M | — | — | — | — | -0.35 | -2.77 | — | -0.05 | -1.53 | -2.77 | 0.00% | — | — | -453.39% | 238.23% | -143.53% | 0.00 | — | 0.72 | 0.67 | 0.30 | 2305.00% | — | 4577.00% | -278.78% | -2.19 | 214.01% | 0.00% | 0.00% | 63.30% | -0.05 | -0.05 | — | -241.19 |
| LEXX | Lexaria Bioscience Corp. | $0.70 | 13.51M | +3,989% | -40% | — | — | -1.57 | 6.26 | 26.52 | -1.43 | -3.89 | 6.98 | 83.20% | -1647.97% | -1686.00% | -216.06% | -846.18% | -182.65% | 0.04 | — | 2.32 | 1.56 | 0.14 | 4043.00% | 5205.00% | 10942.00% | -55.96% | -7.00 | -761.93% | 0.00% | 0.00% | 0.00% | -1.45 | -1.61 | 23.88 | -22.60 |
| MLEC | Moolec Science S.A. | $13.30 | 9.66M | +7,515% | +24,189,467% | — | — | -0.07 | -0.12 | 0.02 | -3.56 | 0.00 | -0.05 | 34.17% | -3.14% | -33.41% | 376.84% | -11.15% | -93.08% | -3.74 | -0.25 | 0.13 | 0.12 | -3.57 | 897895.00% | 583074.00% | 21733.00% | -393.07% | -0.10 | -32.03% | 0.00% | 0.00% | 12.10% | -23.43 | -8.16 | 0.74 | -0.48 |
| NCEL | NewcelX Ltd. | $2.90 | 1.31M | — | — | — | — | -0.65 | 0.91 | — | 0.11 | -0.09 | 0.91 | 0.00% | — | — | 53.34% | 104.83% | -97.10% | 0.00 | -29.20 | 2.69 | 2.50 | 0.46 | 72188.00% | — | -5589.00% | -333.71% | -5.16 | 102.24% | 0.00% | 0.00% | 187.60% | 0.09 | 0.09 | — | -51.45 |
| VRAX | Virax Biolabs Group Limit… | $0.23 | 988.66K | +58,899% | +71% | — | +71,836% | -0.50 | 0.53 | 478.92 | 0.14 | — | 0.54 | -838.21% | -97344.76% | -95739.17% | -109.69% | -313.42% | -101.88% | 0.07 | -105.93 | 7.27 | 6.33 | 0.66 | -4196.00% | -9595.00% | -3028.00% | -170.43% | -6.78 | -268.72% | 0.00% | 0.00% | 16.06% | 0.13 | 0.16 | -129.50 | -5.85 |
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
- CEO
- Allen Warren Davidoff
- Employees
- 2
- Beta
- 0.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.78) − 1 = — (DCF, example).